Logo image of LEG

LEGGETT & PLATT INC (LEG) Stock Fundamental Analysis

NYSE:LEG - New York Stock Exchange, Inc. - US5246601075 - Common Stock - Currency: USD

9.89  -0.04 (-0.4%)

After market: 9.89 0 (0%)

Fundamental Rating

3

LEG gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 64 industry peers in the Household Durables industry. LEG has a bad profitability rating. Also its financial health evaluation is rather negative. LEG has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

In the past year LEG was profitable.
In the past year LEG had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: LEG reported negative net income in multiple years.
Each year in the past 5 years LEG had a positive operating cash flow.
LEG Yearly Net Income VS EBIT VS OCF VS FCFLEG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M

1.2 Ratios

LEG has a Return On Assets of -13.67%. This is amonst the worse of the industry: LEG underperforms 87.50% of its industry peers.
LEG has a Return On Equity of -68.63%. This is amonst the worse of the industry: LEG underperforms 90.63% of its industry peers.
Looking at the Return On Invested Capital, with a value of 6.99%, LEG is in line with its industry, outperforming 51.56% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for LEG is below the industry average of 10.34%.
Industry RankSector Rank
ROA -13.67%
ROE -68.63%
ROIC 6.99%
ROA(3y)-3.65%
ROA(5y)0.38%
ROE(3y)-21.86%
ROE(5y)-4.68%
ROIC(3y)8%
ROIC(5y)8.74%
LEG Yearly ROA, ROE, ROICLEG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60

1.3 Margins

LEG has a Operating Margin (6.03%) which is comparable to the rest of the industry.
In the last couple of years the Operating Margin of LEG has declined.
Looking at the Gross Margin, with a value of 17.73%, LEG is doing worse than 82.81% of the companies in the same industry.
In the last couple of years the Gross Margin of LEG has declined.
Industry RankSector Rank
OM 6.03%
PM (TTM) N/A
GM 17.73%
OM growth 3Y-18.8%
OM growth 5Y-10.74%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.29%
GM growth 5Y-4.1%
LEG Yearly Profit, Operating, Gross MarginsLEG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20

3

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), LEG is creating some value.
The number of shares outstanding for LEG has been increased compared to 1 year ago.
LEG has more shares outstanding than it did 5 years ago.
LEG has a worse debt/assets ratio than last year.
LEG Yearly Shares OutstandingLEG Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
LEG Yearly Total Debt VS Total AssetsLEG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.2 Solvency

An Altman-Z score of 2.74 indicates that LEG is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of LEG (2.74) is comparable to the rest of the industry.
LEG has a debt to FCF ratio of 7.76. This is a slightly negative value and a sign of low solvency as LEG would need 7.76 years to pay back of all of its debts.
LEG's Debt to FCF ratio of 7.76 is in line compared to the rest of the industry. LEG outperforms 56.25% of its industry peers.
LEG has a Debt/Equity ratio of 2.59. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of LEG (2.59) is worse than 93.75% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.59
Debt/FCF 7.76
Altman-Z 2.74
ROIC/WACC0.91
WACC7.68%
LEG Yearly LT Debt VS Equity VS FCFLEG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.3 Liquidity

LEG has a Current Ratio of 2.20. This indicates that LEG is financially healthy and has no problem in meeting its short term obligations.
LEG's Current ratio of 2.20 is in line compared to the rest of the industry. LEG outperforms 46.88% of its industry peers.
LEG has a Quick Ratio of 1.36. This is a normal value and indicates that LEG is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Quick ratio value of 1.36, LEG is doing good in the industry, outperforming 70.31% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.2
Quick Ratio 1.36
LEG Yearly Current Assets VS Current LiabilitesLEG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

3

3. Growth

3.1 Past

LEG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -13.82%.
The earnings per share for LEG have been decreasing by -16.39% on average. This is quite bad
Looking at the last year, LEG shows a decrease in Revenue. The Revenue has decreased by -6.51% in the last year.
The Revenue has been decreasing by -1.60% on average over the past years.
EPS 1Y (TTM)-13.82%
EPS 3Y-27.71%
EPS 5Y-16.39%
EPS Q2Q%4.35%
Revenue 1Y (TTM)-6.51%
Revenue growth 3Y-4.75%
Revenue growth 5Y-1.6%
Sales Q2Q%-6.82%

3.2 Future

LEG is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.87% yearly.
LEG is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.83% yearly.
EPS Next Y6.29%
EPS Next 2Y8.55%
EPS Next 3Y9.37%
EPS Next 5Y8.87%
Revenue Next Year-4.73%
Revenue Next 2Y-1.43%
Revenue Next 3Y-0.27%
Revenue Next 5Y0.83%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LEG Yearly Revenue VS EstimatesLEG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1B 2B 3B 4B 5B
LEG Yearly EPS VS EstimatesLEG Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0.5 1 1.5 2 2.5

6

4. Valuation

4.1 Price/Earnings Ratio

LEG is valuated reasonably with a Price/Earnings ratio of 9.33.
Compared to the rest of the industry, the Price/Earnings ratio of LEG indicates a somewhat cheap valuation: LEG is cheaper than 62.50% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.45, LEG is valued rather cheaply.
With a Price/Forward Earnings ratio of 7.99, the valuation of LEG can be described as very cheap.
Based on the Price/Forward Earnings ratio, LEG is valued a bit cheaper than the industry average as 79.69% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of LEG to the average of the S&P500 Index (21.90), we can say LEG is valued rather cheaply.
Industry RankSector Rank
PE 9.33
Fwd PE 7.99
LEG Price Earnings VS Forward Price EarningsLEG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

LEG's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. LEG is cheaper than 65.63% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, LEG is valued cheaper than 93.75% of the companies in the same industry.
Industry RankSector Rank
P/FCF 5.35
EV/EBITDA 7.25
LEG Per share dataLEG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

LEG's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PEG (NY)1.48
PEG (5Y)N/A
EPS Next 2Y8.55%
EPS Next 3Y9.37%

3

5. Dividend

5.1 Amount

LEG has a Yearly Dividend Yield of 2.02%.
LEG's Dividend Yield is a higher than the industry average which is at 3.29.
Compared to an average S&P500 Dividend Yield of 2.38, LEG has a dividend comparable with the average S&P500 company.
Industry RankSector Rank
Dividend Yield 2.02%

5.2 History

The dividend of LEG decreases each year by -8.18%.
LEG has been paying a dividend for at least 10 years, so it has a reliable track record.
Dividend Growth(5Y)-8.18%
Div Incr Years0
Div Non Decr Years0
LEG Yearly Dividends per shareLEG Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.5 1 1.5

5.3 Sustainability

The earnings of LEG are negative and hence is the payout ratio. LEG will probably not be able to sustain this dividend level.
DP-15.94%
EPS Next 2Y8.55%
EPS Next 3Y9.37%
LEG Yearly Income VS Free CF VS DividendLEG Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M

LEGGETT & PLATT INC

NYSE:LEG (7/3/2025, 7:44:12 PM)

After market: 9.89 0 (0%)

9.89

-0.04 (-0.4%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Durables & Apparel
GICS IndustryHousehold Durables
Earnings (Last)04-28 2025-04-28/amc
Earnings (Next)07-30 2025-07-30/amc
Inst Owners79.74%
Inst Owner Change3.67%
Ins Owners0.87%
Ins Owner Change11.19%
Market Cap1.34B
Analysts49.09
Price Target10.2 (3.13%)
Short Float %6.65%
Short Ratio3.12
Dividend
Industry RankSector Rank
Dividend Yield 2.02%
Yearly Dividend1.02
Dividend Growth(5Y)-8.18%
DP-15.94%
Div Incr Years0
Div Non Decr Years0
Ex-Date06-13 2025-06-13 (0.05)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.96%
Min EPS beat(2)2.68%
Max EPS beat(2)9.25%
EPS beat(4)2
Avg EPS beat(4)1.3%
Min EPS beat(4)-3.49%
Max EPS beat(4)9.25%
EPS beat(8)2
Avg EPS beat(8)-2.38%
EPS beat(12)4
Avg EPS beat(12)1.23%
EPS beat(16)7
Avg EPS beat(16)3.05%
Revenue beat(2)1
Avg Revenue beat(2)0.5%
Min Revenue beat(2)-0.77%
Max Revenue beat(2)1.77%
Revenue beat(4)1
Avg Revenue beat(4)-0.62%
Min Revenue beat(4)-2.07%
Max Revenue beat(4)1.77%
Revenue beat(8)1
Avg Revenue beat(8)-1.74%
Revenue beat(12)3
Avg Revenue beat(12)-1.15%
Revenue beat(16)6
Avg Revenue beat(16)-0.33%
PT rev (1m)0%
PT rev (3m)-14.29%
EPS NQ rev (1m)1.68%
EPS NQ rev (3m)-4.72%
EPS NY rev (1m)1.14%
EPS NY rev (3m)-0.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.84%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.04%
Valuation
Industry RankSector Rank
PE 9.33
Fwd PE 7.99
P/S 0.31
P/FCF 5.35
P/OCF 4.2
P/B 1.79
P/tB N/A
EV/EBITDA 7.25
EPS(TTM)1.06
EY10.72%
EPS(NY)1.24
Fwd EY12.51%
FCF(TTM)1.85
FCFY18.68%
OCF(TTM)2.36
OCFY23.84%
SpS31.88
BVpS5.53
TBVpS-0.64
PEG (NY)1.48
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.67%
ROE -68.63%
ROCE 8.84%
ROIC 6.99%
ROICexc 8.13%
ROICexgc 12.13%
OM 6.03%
PM (TTM) N/A
GM 17.73%
FCFM 5.79%
ROA(3y)-3.65%
ROA(5y)0.38%
ROE(3y)-21.86%
ROE(5y)-4.68%
ROIC(3y)8%
ROIC(5y)8.74%
ROICexc(3y)8.89%
ROICexc(5y)9.67%
ROICexgc(3y)18.06%
ROICexgc(5y)21.73%
ROCE(3y)10.16%
ROCE(5y)11.09%
ROICexcg growth 3Y-24.14%
ROICexcg growth 5Y-12.98%
ROICexc growth 3Y-12.28%
ROICexc growth 5Y-5.12%
OM growth 3Y-18.8%
OM growth 5Y-10.74%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.29%
GM growth 5Y-4.1%
F-Score5
Asset Turnover1.15
Health
Industry RankSector Rank
Debt/Equity 2.59
Debt/FCF 7.76
Debt/EBITDA 4.9
Cap/Depr 51.22%
Cap/Sales 1.6%
Interest Coverage 250
Cash Conversion 80.74%
Profit Quality N/A
Current Ratio 2.2
Quick Ratio 1.36
Altman-Z 2.74
F-Score5
WACC7.68%
ROIC/WACC0.91
Cap/Depr(3y)59.68%
Cap/Depr(5y)54.18%
Cap/Sales(3y)2.07%
Cap/Sales(5y)1.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-13.82%
EPS 3Y-27.71%
EPS 5Y-16.39%
EPS Q2Q%4.35%
EPS Next Y6.29%
EPS Next 2Y8.55%
EPS Next 3Y9.37%
EPS Next 5Y8.87%
Revenue 1Y (TTM)-6.51%
Revenue growth 3Y-4.75%
Revenue growth 5Y-1.6%
Sales Q2Q%-6.82%
Revenue Next Year-4.73%
Revenue Next 2Y-1.43%
Revenue Next 3Y-0.27%
Revenue Next 5Y0.83%
EBIT growth 1Y-14.87%
EBIT growth 3Y-22.65%
EBIT growth 5Y-12.17%
EBIT Next Year51.98%
EBIT Next 3Y19.57%
EBIT Next 5Y12.8%
FCF growth 1Y-34.28%
FCF growth 3Y10.81%
FCF growth 5Y-15.65%
OCF growth 1Y-36.17%
OCF growth 3Y4.06%
OCF growth 5Y-14.47%